This quarter, we also learned that the FOLFIRINOX chemotherapy protocol should be favoured over the current standard in locally advanced unresectable pancreatic cancers, that radionuclide therapy in hard-to-treat prostate cancers improves patients’ quality of life in addition to being effective, that two mutations could be targeted to develop new drugs for a subtype of lung cancer mainly affecting young people, and that a gut bacterium could play a key role in the response to CAR-T cell therapies.